Global Automated Radiosynthesis Modules Market Overview:
Radiosynthesis modules are used for synthesis of radioactive compounds through replacing the one or more atoms present in the radioisotope. Basically, it captures and use the energy derived from the ionizing radiation for development of radioisotopes. It is mostly used in the hospitals or other medical facilities with the main aim of producing radiotracers. Radiotracers are used in diagnosis, imaging, and therapeutic use for treating the patients suffering from chronic and fatal medical conditions such as cancer, cardiac issues, and others. These modules are available in semi-automated and automated type. These are commercialized in table top form, which can be readily used across various healthcare facilities and research institutes.
- Rapidly rising prevalence of chronic medical conditions
- Short life of radiotracers, promoting demand for automated radiosynthesis modules
- Increasing healthcare spending
- High cost of the radiosynthesis modules
- Continuous development in the nuclear medicine along with new radioisotope production technologies
Some of the key players profiled in the report are COMECER S.p.A (Italy), GE Healthcare (US), Siemens Healthcare (Germany), IBA Radiopharma Solutions (Belgium), Optimized Radiochemical Applications (Belgium), Synthra GmbH (Germany), Eckert & Ziegler Group (Germany), Sumitomo Corp (Japan), Sofie Biosciences (US) and Trasis and Scintomics GmbH (Belgium). Analyst at AMA Research see Players are mainly concentrated in Europe Players to retain maximum share of Global Automated Radiosynthesis Modules market by 2025. Considering Market by Type, the sub-segment i.e. Fully Automated will boost the Automated Radiosynthesis Modules market. Considering Market by End-User, the sub-segment i.e. Treatment will boost the Automated Radiosynthesis Modules market.
In 2017, the GE Healthcare entered into partnership with the HealthTrust for exclusive providing low-energy (SPECT) and high-energy (PET) radiopharmaceuticals in the United States. Due to this, the HealthTrust member gets access to Life Sciences Core Imaging single-photon emission computed tomography (SPECT).
In June 2018, Trasis and Shertech Laboratories received Marketing Authorization from the U.S. Food and Drug Administration (US FDA) for the [18F] FDG Dual process on AllinOne modules, which is used in PET to diagnose, and monitor treatment of cancers types.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Automated Radiosynthesis Modules market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Automated Radiosynthesis Modules market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Automated radiosynthesis module and Suppliers of Automated radiosynthesis module.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.